



(51) International Patent Classification:

A61K 31/395 (2006.01) A61K 31/425 (2006.01)  
A61K 31/13 (2006.01) A61K 31/33 (2006.01)  
A61K 31/44 (2006.01)

(21) International Application Number:

PCT/US2025/016504

(22) International Filing Date:

19 February 2025 (19.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


|            |                               |    |
|------------|-------------------------------|----|
| 63/555,860 | 20 February 2024 (20.02.2024) | US |
| 63/574,166 | 03 April 2024 (03.04.2024)    | US |
| 63/683,618 | 15 August 2024 (15.08.2024)   | US |
| 63/743,932 | 10 January 2025 (10.01.2025)  | US |

(71) Applicant: **IAMBIC THERAPEUTICS, INC.** [US/US];  
5627 Oberlin Drive, Suite 120, San Diego, California 92121  
(US).

(72) Inventors: **JOSEPHSON, Neil Cary**; 5627 Oberlin Drive,  
Suite 120, San Diego, California 92121 (US). **MILLER,**  
**Thomas Francis, III**; 5627 Oberlin Drive, Suite 120, San  
Diego, California 92121 (US). **MANBY, Frederick Roy**;  
5627 Oberlin Drive, Suite 120, San Diego, California 92121  
(US). **ZHANG, Chao**; 5627 Oberlin Drive, Suite 120, San  
Diego, California 92121 (US). **WALLING, Jacqueline**  
**Mary**; 5627 Oberlin Drive, Suite 120, San Diego, Califor-  
nia 92121 (US). **BOTROUS, Iriny**; 5627 Oberlin Drive,  
Suite 120, San Diego, California 92121 (US). **DENNIS,**  
**Joseph Michael**; 5627 Oberlin Drive, Suite 120, San Diego,  
California 92121 (US). **KULYK, Svitlana**; 5627 Ober-  
lin Drive, Suite 120, San Diego, California 92121 (US).  
**GOMEZ, Laurent**; 5627 Oberlin Drive, Suite 120, San  
Diego, California 92121 (US). **WRIGHT, Shawn Eric**;  
5627 Oberlin Drive, Suite 120, San Diego, California 92121  
(US). **DERRICOTTE, Wallace Deshaugh**; 5627 Ober-

(54) Title: DOSES AND REGIMENS OF HER2 INHIBITORS

Fig. 11



(57) Abstract: Provided herein are pharmaceutical compositions comprising a compound of having Formula I as described in this disclosure, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutical excipients, wherein the composition is in a unit dosage form; and methods for treating cancer modulated by HER2 in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition or a compound having Formula II as described in this disclosure, or a pharmaceutically acceptable salt thereof, and optionally one or more additional therapeutic agents.

lin Drive, Suite 120, San Diego, California 92121 (US).  
**HUANG, Zhongdong**; 5627 Oberlin Drive, Suite 120, San Diego, California 92121 (US). **GULLAPALLI, Rampurna Prasad**; 5627 Oberlin Drive, Suite 120, San Diego, California 92121 (US).

(74) **Agent: MARGULIEUX, Grant** et al.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*